On March 9, Encysive Pharmaceuticals
- Encysive's Thelin is approved in Europe, and sales should ramp up this year, though the company did not provide sales guidance.
- The company has run into one setback after another in its attempts to get Thelin approved in the U.S. The FDA will issue its next decision in June, the same month it rules on a competing drug, Gilead Sciences'
(NASDAQ:GILD) Ambrisentan. - Failing to garner FDA approval for Thelin has left Encysive on shaky financial footing. The company will need to raise additional funds this year.
(Figures in thousands, except per-share data)
Income Statement Highlights
|
Q4 2006 |
Q4 2005 |
Change |
|
|---|---|---|---|
|
Sales |
$5,440.0 |
$5,579.0 |
(2.5%) |
|
Net Profit |
($25,801.0) |
($19,371.0) |
N/A |
|
EPS |
($0.44) |
($0.33) |
N/A |
|
Diluted Shares |
59,297.0 |
58,201.0 |
1.9% |
Get back to basics with the income statement.
Margin Checkup
|
Q4 2006 |
Q4 2005 |
Change* |
|
|---|---|---|---|
|
Gross Margin |
98.5% |
100.0% |
(1.5) |
|
Operating Margin |
(467.1%) |
(354.6%) |
(112.5) |
|
Net Margin |
(474.3%) |
(347.2%) |
(127.1) |
Margins are the earnings engine.
Balance Sheet Highlights
|
Assets |
Q4 2006 |
Q4 2005 |
Change |
|---|---|---|---|
|
Cash + ST Invest. |
$43,798.0 |
$127,913.0 |
(65.8%) |
|
Accounts Rec. |
No Data |
No Data |
No Data |
|
Inventory |
No Data |
No Data |
No Data |
|
Liabilities |
Q4 2006 |
Q4 2005 |
Change |
|---|---|---|---|
|
Accounts Payable |
No Data |
No Data |
No Data |
|
Long-Term Debt |
$130,000.0 |
$130,000.0 |
0.0% |
The balance sheet reflects the company's health.
Cash Flow Highlights
Perhaps Encysive's cash flow data awaits FDA approval as well? In any case, it's absent from the company's earnings release.
Free cash flow is a Fool's best friend.
Related Foolishness:
- The Best Small Cap for 2007: Encysive Pharmaceuticals
- Another Go for Encysive Drug Trials
- Encysive's Outback Adventures
Fool by Numbers is designed to give you the raw earnings information in a timely fashion, putting all the numbers you need in one easy-to-read place. But at The Motley Fool, we believe numbers tell only part of the story, so check Fool.com for more of our in-depth discussion of what the numbers mean.
Encysive Pharmaceuticals is a Rule Breakers recommendation. Discover more top growth picks from David Gardner and his team with a free 30-day trial subscription.
This data has been provided by Netscribes. To provide feedback on this article, please click on the "feedback" button below.
